Xanthine oxidoreductase in atherosclerosis pathogenesis: Not only oxidative stress

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 562-567

  Battelli, Maria Giulia ^a   Polito, Letizia ^a   Bolognesi, Andrea ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Atherosclerosis; Cardiovascular diseases; Metabolic syndrome; Oxidative stress; Uric acid; Xanthine oxidoreductase

Indexed keywords

ENZYME; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDANTS PRODUCING ENDOTHELIAL ENZYME; UNCLASSIFIED DRUG; URIC ACID; XANTHINE OXIDASE;

ADIPOGENESIS; ARTERY MUSCLE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DIABETES MELLITUS; ENZYME ACTIVITY; FOAM CELL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERURICEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; SMOKING;

EID: 84908568867     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.10.006     Document Type: Review

References (58)

1. Glantzounis G.K., Tsimoyiannis E.C., Kappas A.M., Galaris D.A. Uric acid and oxidative stress. Curr. Pharm. Des. 2005, 11:4145-4151.
2. Della Corte E., Stirpe F. The regulation of rat liver xanthine oxidase. Involvement of thiol groups in the conversion of the enzyme activity from dehydrogenase (type D) into oxidase (type O) and purification of the enzyme. Biochem. J. 1972, 126:739-745.
3. Cantu-Medellin N., Kelley E.E. Redox Biol. 2013, 1:353-358.
4. Nishino T., Okamoto K., Eger B.T., Pai E.F., Nishino T. Mammalian xanthine oxidoreductase - mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J. 2008, 275:3278-3289.
5. Battelli M.G., Bolognesi A., Polito L. Pathophysiology of circulating xanthine oxidoreductase: new roles for a multitasking enzyme. BBA Mol. Bas. Dis. 2014, 1842:1502-1517.
6. Weseler A.R., Bast A. Oxidative stress and vascular function: implications for pharmacologic treatments. Curr. Hypertens. Rep. 2010, 12:154-161.
7. Baker J.E., Su J., Fu X., Hsu A., Gross G.J., Tweddell J.S., Hogg N. Nitrite confers protection against myocardial infarction: role of xanthine oxidoreductase, NADPH oxidase and K(ATP) channels. J.Mol. Cell. Cardiol. 2007, 43:437-444.
8. Boueiz A., Damarla M., Hassoun P.M. Xanthine oxidoreductase in respiratory and cardiovascular disorders. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 294:L830-L840.
9. Pacher P., Nivorozhkin A., Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev. 2006, 58:87-114.
10. Madamanchi N.R., Vendrov A., Runge M.S. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2005, 25:29-38.
11. Patetsios P., Song M., Shutze W.P., Pappas C., Rodino W., Ramirez J.A., Panetta T.F. Identification of uric acid and xanthine oxidase in atherosclerotic plaque. Am. J. Cardiol. 2001, 88:188-191. A6.
12. McNally J.S., Davis M.E., Giddens D.P., Saha A., Hwang J., Dikalov S., Jo H., Harrison D.G. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:H2290-H2297.
13. Sabán-Ruiz J., Alonso-Pacho A., Fabregate-Fuente M., de la Puerta Gonzalez-Quevedo C. Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation. Antiinflamm. Antiallergy Agents Med. Chem. 2013, 12:94-99.
14. Xu X., Hu X., Lu Z., Zhang P., Zhao L., Wessale J.L., Bache R.J., Chen Y. Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J.Card. Fail. 2008, 14:746-753.
15. Sánchez-Lozada L.G., Tapia E., Soto V., Avila-Casado C., Franco M., Zhao L., Johnson R.J. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol. Dial. Transpl. 2008, 23:1179-1185.
16. Hare J.M., Mangal B., Brown J., Fisher C., Freudenberger R., Colucci W.S., Mann D.L., Liu P., Givertz M.M., Schwarz R.P. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J.Am. Coll. Cardiol. 2008, 51:2301-2309. OPT-CHF Investigators.
17. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 2000, 87:840-844.
18. Janssen M., de Jong J.W., Pasini E., Ferrari R. Myocardial xanthine oxidoreductase activity in hypertensive and hypercholesterolemic rats. Cardioscience 1993, 4:25-29.
19. Suzuki H., DeLano F.A., Parks D.A., Jamshidi N., Granger D.N., Ishii H., Suematsu M., Zweifach B.W., Schmid-Schönbein G.W. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4754-4759.
20. Swei A., Lacy F., Delano F.A., Parks D.A., Schmid-Schönbein G.W. Amechanism of oxygen free radical production in the Dahl hypertensive rat. Microcirculation 1999, 6:179-187.
21. Ohtsubo T., Rovira I.I., Starost M.F., Liu C., Finkel T. Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2. Circ. Res. 2004, 95:1118-1124.
22. Szasz T., Davis R.P., Garver H.S., Burnett R.J., Fink G.D., Watts S.W. Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive rats. PLoS One 2013, 8:e56046.
23. Newaz M.A., Yousefipour Z., Oyekan A. Oxidative stress-associated vascular aging is xanthine oxidase-dependent but not NAD(P)H oxidase-dependent. J.Cardiovasc. Pharmacol. 2006, 48:88-94.
24. Ghosh S.M., Kapil V., Fuentes-Calvo I., Bubb K.J., Pearl V., Milsom A.B., Khambata R., Maleki-Toyserkani S., Yousuf M., Benjamin N., Webb A.J., Caulfield M.J., Hobbs A.J., Ahluwalia A. Enhanced vasodilator activity of nitrite in hypertension: critical role for erythrocytic xanthine oxidoreductase and translational potential. Hypertension 2013, 61:1091-1102.
25. Mercuro G., Vitale C., Cerquetani E., Zoncu S., Deidda M., Fini M., Rosano G.M. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am. J. Cardiol. 2004, 94:932-935.
26. Yiginer O., Ozcelik F., Inanc T., Aparci M., Ozmen N., Cingozbay B.Y., Kardesoglu E., Suleymanoglu S., Sener G., Cebeci B.S. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin. Res. Cardiol. 2008, 97:334-340.
27. Higgins P., Dawson J., Lees K.R., McArthur K., Quinn T.J., Walters M.R. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc. Ther. 2012, 30:217-226.
28. Neogi T., George J., Rekhraj S., Struthers A.D., Choi H., Terkeltaub R.A. Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum. 2012, 64:327-338.
29. Watanabe S., Kang D.H., Feng L., Nakagawa T., Kanellis J., Lan H., Mazzali M., Johnson R.J. Hypertension 2002, 40:355-360.
30. Feig D.I. Serum uric acid and the risk of hypertension and chronic kidney disease. Curr. Opin. Rheumatol. 2014, 26:176-185.
31. Kayyali U.S., Budhiraja R., Pennella C.M., Cooray S., Lanzillo J.J., Chalkley R., Hassoun P.M. Upregulation of xanthine oxidase by tobacco smoke condensate in pulmonary endothelial cells. Toxicol. Appl. Pharmacol. 2003, 188:59-68.
32. Lehr H.A., Kress E., Menger M.D., Friedl H.P., Hübner C., Arfors K.E., Messmer K. Cigarette smoke elicits leukocyte adhesion to endothelium in hamsters: inhibition by CuZn-SOD. Free Radic. Biol. Med. 1993, 14:573-581.
33. Kim B.S., Serebreni L., Hamdan O., Wang L., Parniani A., Sussan T., Scott Stephens R., Boyer L., Damarla M., Hassoun P.M., Damico R. Xanthine oxidoreductase is a critical mediator of cigarette smoke-induced endothelial cell DNA damage and apoptosis. Free Radic. Biol. Med. 2013, 60:336-346.
34. Guthikonda S., Sinkey C., Barenz T., Haynes W.G. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 2003, 107:416-421.
35. Guthikonda S., Woods K., Haynes W.G. Role of xanthine oxidase in conduit artery endothelial dysfunction in cigarette smokers. Am. J. Cardiol. 2004, 93:664-668.
36. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J.Clin. Invest. 1993, 91:2546-2551.
37. Mügge A., Brandes R.P., Böger R.H., Dwenger A., Bode-Böger S., Kienke S., Frölich J.C., Lichtlen P.R. Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J.Cardiovasc. Pharmacol. 1994, 24:994-998.
38. White C.R., Darley-Usmar V., Berrington W.R., McAdams M., Gore J.Z., Thompson J.A., Parks D.A., Tarpey M.M., Freeman B.A. Circulating plasma xanthine oxidase contributes to vascular disfunction in hypercholesterolemic rabbits. Proc. Natl. Acad. Sci. 1996, 93:8745-8749.
39. Desco M.C., Asensi M., Márquez R., Martínez-Valls J., Vento M., Pallardó F.V., Sastre J., Viña J. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002, 51:1118-1124.
40. Cardillo C., Kilcoyne C.M., Cannon R.O., Quyyumi A.A., Panza J.A. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997, 30:57-63.
41. Spiekermann S., Landmesser U., Dikalov S., Bredt M., Gamez G., Tatge H., Reepschlager N., Hornig B., Drexler H., Harrison D. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2003, 107:1383-1389.
42. Real J.T., Martínez-Hervás S., García-García A.B., Civera M., Pallardó F.V., Ascaso J.F., Viña J.R., Chaves F.J., Carmena R. Circulating mononuclear cells nuclear factor-kappa B activity, plasma xanthine oxidase, and low grade inflammatory markers in adult patients with familial hypercholesterolaemia. Eur. J. Clin. Invest. 2010, 40:89-94.
43. Kushiyama A., Okubo H., Sakoda H., Kikuchi T., Fujishiro M., Sato H., Kushiyama S., Iwashita M., Nishimura F., Fukushima T., Nakatsu Y., Kamata H., Kawazu S., Higashi Y., Kurihara H., Asano T. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. Arterioscler. Thromb. Vasc. Biol. 2012, 32:291-298.
44. Rajsheker S., Manka D., Blomkalns A.L., Chatterjee T.K., Stoll L.L., Weintraub N.L. Crosstalk between perivascular adipose tissue and blood vessels. Curr. Opin. Pharmacol. 2010, 10:191-196.
45. Stephens J.M. The fat controller: adipocyte development. PLoS Biol. 2012, 10:e1001436.
46. Erdei N., Tóth A., Pásztor E.T., Papp Z., Edes I., Koller A., Bagi Z. High-fat diet-induced reduction in nitric oxide-dependent arteriolar dilation in rats: role of xanthine oxidase-derived superoxide anion. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H2107-H2115.
47. Butler R., Morris A.D., Belch J.J., Hill A., Struthers A.D. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000, 35:746-751.
48. Ćosić V., Antić S., Pesić M., Jovanović O., Kundalić S., Djordjević V.B. Monotherapy with metformin: does it improve hypoxia in type 2 diabetic patients?. Clin. Chem. Lab. Med. 2001, 39:818-821.
49. Martinez-Hervas S., Real J.T., Ivorra C., Priego A., Chaves F.J., Pallardo F.V., Viña J.R., Redon J., Carmena R., Ascaso J.F. Increased plasma xanthine oxidase activity is related to nuclear factor kappa beta activation and inflammatory markers in familial combined hyperlipidemia. Nutr. Metab. Cardiovasc. Dis. 2010, 20:734-739.
50. Watson J.D. Type 2 diabetes as a redox disease. Lancet 2014, 383:841-843.
51. Feoli A.M., Macagnan F.E., Piovesan C.H., Bodanese L.C., Siqueira I.R. Xanthine oxidase activity is associated with risk factors for cardiovascular disease and inflammatory and oxidative status markers in metabolic syndrome: effects of a single exercise session. Oxid. Med. Cell. Longev. 2014, 2014:587083. (Epub 2014 May 21). 10.1155/2014/587083.
52. Varga Z.V., Giricz Z., Liaudet L., Haskó G., Ferdinandy P., Pacher P. Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. Biochim. Biophys. Acta 2014 Jul 2, pii: S0925-4439(14)00207-5. (Epub ahead of print). 10.1016/j.bbadis.2014.06.030.
53. Cheung K.J., Tzameli I., Pissios P., Rovira I., Gavrilova O., Ohtsubo T., Chen Z., Finkel T., Flier J.S., Friedman J.M. Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell. Metab. 2007, 5:115-128.
54. Vorbach C., Scriven A., Capecchi M.R. The housekeeping gene xanthine oxidoreductase is necessary for milk fat droplet enveloping and secretion: gene sharing in the lactating mammary gland. Genes. Dev. 2002, 16:3223-3235.
55. Ohtsubo T., Matsumura K., Sakagami K., Fujii K., Tsuruya K., Noguchi H., Rovira I.I., Finkel T., Iida M. Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules. Hypertension 2009, 54:868-876.
56. Chung H.Y., Baek B.S., Song S.H., Kim M.S., Huh J.I., Shim K.H., Kim K.W., Lee K.H. Xanthine dehydrogenase/xanthine oxidase and oxidative stress. Age 1997, 20:127-140.
57. Linder N., Bützow R., Lassus H., Lundin M., Lundin J. Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma. Gynecol. Oncol. 2012, 124:311-318.
58. Tenenbaum A., Fisman E.Z. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?. Cardiovasc. Diabetol. 2012, 11:140-148.